Our results highlight the potential of targeting the Arg1/polyamine‐mediated DCs/Th17 axis by scavenging self‐antigens with nor@MSC‐EVs in clinically ameliorating psoriasis symptoms and providing an alternative for psoriasis therapy. Here, ARG1 is linked to psoriasis.